[SCHEDULE 13G] Silexion Therapeutics Corp SEC Filing

Rhea-AI Filing Summary

Lincoln Alternative Strategies LLC reported beneficial ownership of 131,250 ordinary shares of Silexion Therapeutics Corp., representing 6.18% of the outstanding common stock based on 2,123,892 shares outstanding as of September 12, 2025. The filing on Schedule 13G states the shares are held with sole voting and dispositive power and that they were not acquired to change or influence control of the issuer. The report lists the filers Delaware organization, principal address in Miami Beach, FL, and is signed by Stephen Temes as Managing Member on September 15, 2025.

Positive

• Material stake disclosed: Reporting person holds 131,250 shares (6.18%) of Silexion Therapeutics, a meaningful ownership level above 5%.

Negative

• None.

Insights

Financial Analyst

TL;DR: A Delaware investment manager disclosed a meaningful 6.18% stake in SLXN with sole voting and dispositive power.

The Schedule 13G indicates Lincoln Alternative Strategies LLC beneficially owns 131,250 shares, equal to 6.18% of Silexion Therapeutics outstanding stock based on the filings share count. Sole voting and dispositive power suggests direct control over voting decisions for these shares. The filer certified the stake was not acquired to change control, consistent with passive investor reporting under Schedule 13G. This position size is material for shareholder registers and may be relevant to liquidity and shareholder composition analyses.

Corporate Governance Expert

TL;DR: The filing is a passive ownership disclosure showing a single entity holds >5% with full voting authority.

Lincoln Alternative Strategies LLC is identified as the reporting person and confirms sole voting and dispositive power over 131,250 shares. The Schedule 13G classification and signed certification indicate the filer considers this a passive position not intended to influence control. For governance records, this disclosure updates the list of shareholders above the 5% threshold and clarifies no group affiliations or parent-subsidiary reporting are claimed.

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

Silexion Therapeutics Corp.

(Name of Issuer)

Ordinary Shares, par value $0.0009 per share

(Title of Class of Securities)

G1281K122

(CUSIP Number)

09/12/2025

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

SCHEDULE 13G

CUSIP No. G1281K122

1

Names of Reporting Persons

Lincoln Alternative Strategies LLC

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 131,250.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 131,250.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

131,250.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

6.18 %

12

Type of Reporting Person (See Instructions)

OO

Comment for Type of Reporting Person: Beneficial ownership percentage is based on 2,123,892 shares of the Issuer's common stock issued and outstanding as of September 12, 2025.

SCHEDULE 13G

Item 1.
(a)	Name of issuer: Silexion Therapeutics Corp.
(b)	Address of issuer's principal executive offices: 12 Abba Hillel Road, Ramat-Gan, L3, 52522
Item 2.
(a)	Name of person filing: Lincoln Alternative Strategies LLC
(b)	Address or principal business office or, if none, residence: 404 Washington Ave., Suite 650, Miami Beach, FL 33139
(c)	Citizenship: Delaware
(d)	Title of class of securities: Ordinary Shares, par value $0.0009 per share
(e)	CUSIP No.: G1281K122
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: 131,250
(b)	Percent of class: 6.18%
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: 131,250
	(ii) Shared power to vote or to direct the vote: 0
	(iii) Sole power to dispose or to direct the disposition of: 131,250
	(iv) Shared power to dispose or to direct the disposition of: 0
Item 5.	Ownership of 5 Percent or Less of a Class.
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	Not Applicable
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not Applicable
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Lincoln Alternative Strategies LLC

Signature:	/s/ Stephen Temes
Name/Title:	Stephen Temes/Managing Member
Date:	09/15/2025

FAQ

Who filed the Schedule 13G for Silexion Therapeutics (SLXN)?

Lincoln Alternative Strategies LLC filed the Schedule 13G; signature provided by Stephen Temes, Managing Member on September 15, 2025.

How many Silexion shares does Lincoln Alternative Strategies own and what percent is that?

131,250 shares, which the filing states represent 6.18% of the outstanding common stock based on 2,123,892 shares outstanding as of September 12, 2025.

Does the filer have voting or dispositive power over the shares?

Yes. The filing reports sole voting power and sole dispositive power over 131,250 shares and no shared power.

Was the stake reported as intended to change or influence control of Silexion?

No. The filer certified the securities were not acquired and are not held for the purpose of changing or influencing control of the issuer.

What address and citizenship are listed for the reporting person?

The filers principal business address is 404 Washington Ave., Suite 650, Miami Beach, FL 33139 and citizenship/place of organization is Delaware.